Opportunity
Amblyopia, commonly known as "lazy eye," is a neurodevelopmental vision disorder characterized by decreased vision in one or both eyes due to abnormal visual stimulation during early childhood's critical period of visual development. This condition arises from improper stimulation of nerve pathways between the brain and the eye. Current standard treatments, such as occlusion therapy (patching the stronger eye), optical correction (glasses or lenses), and pharmacological agents like Levodopa/Carbidopa, suffer from significant limitations. Occlusion therapy often requires prolonged use, leading to poor patient adherence, especially in children. Optical approaches are primarily effective only for refractive errors like nearsightedness or astigmatism. Pharmacological options can have unpleasant side effects (e.g., bad taste from Levodopa) or limited efficacy due to issues like poor blood-brain barrier penetration (e.g., Carbidopa). Crucially, these therapies are most effective during childhood and demonstrate markedly deficient results in adults. This is because the brain's visual cortex loses its plasticity after the critical period closes, making it extremely difficult to restore the necessary neural connections for the weaker eye in mature individuals. Consequently, there is a pressing, unmet clinical need for novel therapeutic strategies that can effectively treat amblyopia, particularly in adult patients who have not benefited from traditional childhood interventions, by reopening or restoring visual plasticity.
Technology
The present invention provides a novel therapeutic method centered on administering a therapeutically effective amount of a Cholecystokinin Receptor B (CCKBR) agonist to a subject in need thereof for treating or preventing amblyopia and for regaining or improving visual acuity. The core innovation lies in the surprising discovery that CCKBR agonists can reactivate visual cortical plasticity, effectively "re-opening" a critical period-like state even in adulthood. This addresses the fundamental limitation of existing therapies which fail in adults due to the loss of neural plasticity. The technology involves specific CCKBR agonists such as the synthetic compound 3r1 (Ac-Trp-Nle-Asp-Phe(3-Br)—NH₂) or the natural agonist CCK8s. These compounds are believed to act via CCKB receptors in the brain to facilitate the recovery of lost synaptic plasticity in the visual cortex. Key technical parameters include administration routes like intraperitoneal injection (which offers good bioavailability and allows the agonist to cross the blood-brain barrier), a dosage range from about 10 nM/kg to about 4.18 µM/kg (with a low effective dose of ~0.0122 mg/kg minimizing side effects), and a treatment frequency such as four times a week for a period ranging from about two weeks to six months. Experimental data from mouse models of amblyopia (Long-Term Monocular Deprivation) demonstrate that treatment with CCKBR agonists like 3r1 or CCK8s significantly reverses ocular dominance shifts in the visual cortex and restores visual acuity to levels comparable to normal, non-amblyopic subjects.
Advantages
- Offers a potential treatment for amblyopia in adults, a population with very limited effective options.
- Reactivates visual cortical plasticity, addressing the root cause of treatment resistance in mature individuals.
- Utilizes low effective dosages (e.g., ~0.0122 mg/kg), which may minimize potential side effects.
- Synthetic agonists like 3r1 have a longer half-life than natural agonists and can effectively cross the blood-brain barrier.
- Shows efficacy with a relatively short treatment duration (e.g., significant results observed after 7 days of treatment in animal models).
- Provides a pharmacological alternative to occlusion therapy, potentially improving patient compliance.
- Demonstrated effectiveness in restoring visual acuity and rebalancing ocular dominance in preclinical animal models.
Applications
- Treatment of amblyopia (lazy eye) in pediatric patients.
- Treatment of amblyopia in adult patients who did not receive or respond to childhood therapy.
- Prevention of amblyopia in subjects at high risk.
- Improvement or recovery of visual acuity in subjects with amblyopia.
- Manufacture of medicaments (e.g., injectable solutions or oral formulations) containing CCKBR agonists for ophthalmic use.
- Potential application in other neurological conditions where restoring brain plasticity is therapeutic.
